RSS

Paragon Bioservices

Contract drug manufacturer Catalent has completed its $1.2 billion acquisition of gene therapy manufacturer Paragon Bioservices, the company has announced. Read more

News

Contract drug manufacturer Catalent has announced it is to acquire leading gene therapy company Paragon Bioservices for $1.2 billion. Read more

News